UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

A monocentric retrospective study of 138 therapy-related myeloid neoplasms

Annals of hematology, 2018-12, Vol.97 (12), p.2319-2324

2018

Volltextzugriff (PDF)

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations

Haematologica (Roma), 2015-07, Vol.100 (7), p.893

2015

Volltextzugriff (PDF)

The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)

Haematologica (Roma), 2011-06, Vol.96 (6), p.922-926

2011

Volltextzugriff (PDF)

FIP1L1‐PDGFRα p.T674I‐D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1‐PDGFRα Positive Leukemia

HemaSphere, 2019-04, Vol.3 (2), p.e182-n/a

2019

Volltextzugriff (PDF)

Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen

Haematologica (Roma), 2009-10, Vol.94 (10), p.1440-1444

2009

Volltextzugriff (PDF)

Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia

Expert review of anticancer therapy, 2009-09, Vol.9 (9), p.1295-1304

2009

Volltextzugriff (PDF)

ETV6 and PDGFRB: a license to fuse

Haematologica (Roma), 2007-02, Vol.92 (2), p.145-147

2007

Volltextzugriff (PDF)

t(9;12)(q22;p13) ETV6::SYK: A new recurrent cytogenetic aberration and tyrosine kinase gene fusion in myeloid or lymphoid neoplasms associated with eosinophilia

British journal of haematology, 2023-03, Vol.200 (5), p.665-668

2023

Volltextzugriff (PDF)

Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2–positive chronic eosinophilic leukemia

Blood, 2012-08, Vol.120 (7), p.1529-1531

2012

Volltextzugriff (PDF)

Next generation sequencing in therapy-related myeloid neoplasms compared to de novo myeloid neoplasms

Acta clinica belgica (English ed. Online), 2022-06, Vol.77 (3), p.658-663

2022

Volltextzugriff (PDF)

External quality assessment for molecular diagnostic laboratories in Belgium: Can we improve it?

Accreditation and quality assurance, 2020-02, Vol.25 (1), p.39-49

2020

Volltextzugriff (PDF)

Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel

Cancers, 2019-12, Vol.11 (12), p.2030

2019

Volltextzugriff (PDF)

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA

Experimental hematology, 2014-04, Vol.42 (4), p.282-293.e4

2014

Volltextzugriff (PDF)

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene

Annals of hematology, 2015-11, Vol.94 (11), p.1927-1928

2015

Volltextzugriff (PDF)

Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

Blood, 2006-08, Vol.108 (4), p.1374-1376

2006

Volltextzugriff (PDF)

In Vitro Characterization of Peripheral Blood Progenitor Cell Differentiation and Platelet Function in Essential Thrombocythemia (ET)

Blood, 2014-12, Vol.124 (21), p.1877-1877

2014

Volltextzugriff (PDF)

JAK2 V617F-Negative and MPL W515K/L-Negative Essential Thrombocythemia: A High Resolution SNP Array Study

Blood, 2013-11, Vol.122 (21), p.5258-5258

2013

Volltextzugriff (PDF)

MPL p.S204P Is a Recurrent Mutation in Essential Thrombocythemia

Blood, 2015-12, Vol.126 (23), p.2837-2837

2015

Volltextzugriff (PDF)

Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1

British journal of haematology, 2014-06, Vol.165 (5), p.734-737

2014

Volltextzugriff (PDF)

Screening of JAK 2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN 2, DNAJC 17, ST 13, TOP 1 MT , and NTRK 1

British journal of haematology, 2014-06, Vol.165 (5), p.734-737

2014

Volltextzugriff (PDF)

FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive Leukemia

HemaSphere, 2019-02, p.1

2019

Volltextzugriff (PDF)

Analysis of Genotype, Phenotype and Outcome in a Belgian Cohort of Essential Thrombocythemia

Blood, 2014-12, Vol.124 (21), p.5584-5584

2014

Volltextzugriff (PDF)

Screening JAK2 V617F-Negative and MPL W515K/L-Negative Essential Thrombocythemia Patients For Mutations In SESN2, DNAJC17, ST13, TOP1MT, and NTRK1

Blood, 2013-11, Vol.122 (21), p.5264-5264

2013

Volltextzugriff (PDF)

Translocation t(1;6)(p35.3;p25.2) Involves RCC1 and IRF4 and Is Not Restricted to Unmutated Chronic Lymphocytic Leukemia

Blood, 2012-11, Vol.120 (21), p.4584-4584

2012

Volltextzugriff (PDF)

The Kinase Inhibitor TKI258 Is Active Against the Novel CUX1-FGFR1 Fusion Detected In a Patient with T-Lymphoblastic Leukemia/Lymphoma and t(7;8)(q22;p11)

Blood, 2010-11, Vol.116 (21), p.2715-2715

2010

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(34)
Berichte
(1)

Sprache

Englisch
(35)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(15)
Humans
(14)
Hematology
(13)
Female
(6)
Male
(6)
Adult
(5)
Aged
(5)
Hypereosinophilic Syndrome - Drug Therapy
(5)
Oncogene Proteins, Fusion - Genetics
(5)
Biological And Medical Sciences
(4)
Hematologic And Hematopoietic Diseases
(4)
Medical Sciences
(4)
Mutation
(4)
Oncogene Proteins, Fusion - Metabolism
(4)
Oncology
(4)
Tumors
(4)
Benzamides
(3)
Cell Line, Tumor
(3)
Cell Proliferation - Drug Effects
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A monocentric retrospective study of 138 therapy-related myeloid neoplasms

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations

The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)

FIP1L1‐PDGFRα p.T674I‐D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1‐PDGFRα Positive Leukemia

Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen

Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia

ETV6 and PDGFRB: a license to fuse

t(9;12)(q22;p13) ETV6::SYK: A new recurrent cytogenetic aberration and tyrosine kinase gene fusion in myeloid or lymphoid neoplasms associated with eosinophilia

Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2–positive chronic eosinophilic leukemia

Next generation sequencing in therapy-related myeloid neoplasms compared to de novo myeloid neoplasms

External quality assessment for molecular diagnostic laboratories in Belgium: Can we improve it?

Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene

Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

In Vitro Characterization of Peripheral Blood Progenitor Cell Differentiation and Platelet Function in Essential Thrombocythemia (ET)

JAK2 V617F-Negative and MPL W515K/L-Negative Essential Thrombocythemia: A High Resolution SNP Array Study

MPL p.S204P Is a Recurrent Mutation in Essential Thrombocythemia

Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1

Screening of JAK 2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN 2, DNAJC 17, ST 13, TOP 1 MT , and NTRK 1

FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive Leukemia

Analysis of Genotype, Phenotype and Outcome in a Belgian Cohort of Essential Thrombocythemia

Screening JAK2 V617F-Negative and MPL W515K/L-Negative Essential Thrombocythemia Patients For Mutations In SESN2, DNAJC17, ST13, TOP1MT, and NTRK1

Translocation t(1;6)(p35.3;p25.2) Involves RCC1 and IRF4 and Is Not Restricted to Unmutated Chronic Lymphocytic Leukemia

The Kinase Inhibitor TKI258 Is Active Against the Novel CUX1-FGFR1 Fusion Detected In a Patient with T-Lymphoblastic Leukemia/Lymphoma and t(7;8)(q22;p11)

Suchergebnisse filtern